netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Formulary Chapter 4: Central nervous system - Full Chapter
04.09.01  Expand sub section  Dopaminergic drugs used in Parkinsons disease
04.09.01  Expand sub section  Dopamine receptor agonists
View adult BNF View SPC online View childrens BNF  Track Changes
Amber E

APO-go PEN 30mg/3ml Solution for Injection
APO-go 50mg/5ml Solution for Injection Amps
APO-go PFS 50mg/10ml Solution for Infusion pre-filled syringes

Link to ESCA

Pramipexole (Prescribe MR prep by brand )
View adult BNF View SPC online View childrens BNF  Track Changes

Pramipexole 0.088 mg tablets
Pramipexole 0.18 mg tablets
Pramipexole 0.35 mg tablets
Pramipexole 0.70 mg tablets

Pipexus 0.26 mg prolonged-release tablets
Pipexus 0.52 mg prolonged-release tablets
Pipexus 1.05 mg prolonged-release tablets
Pipexus 1.57 mg prolonged-release tablets
Pipexus 2.10 mg prolonged-release tablets
Pipexus 2.62 mg prolonged-release tablets
Pipexus 3.15 mg prolonged-release tablets

Restriction: Initiation by specialist

Pipexus© is the preferred cost-effective MR Brand (Applicable in primary care). 

View adult BNF View SPC online View childrens BNF  Track Changes

Restriction: Initiation and stabilisation by specialist

Ropinirole Hydrochloride Tab 250mcg 
Ropinirole Hydrochloride Tab 500mcg
Ropinirole Hydrochloride Tab 1mg 
Ropinirole Hydrochloride Tab 2mg
Ropinirole Hydrochloride Tab 5mg

Ropinirole Hydrochloride Tab 2mg M/R 
Ropinirole Hydrochloride Tab 3mg M/R 
Ropinirole Hydrochloride Tab 4mg M/R 
Ropinirole Hydrochloride Tab 6mg M/R 
Ropinirole Hydrochloride Tab 8mg M/R  

Ipinnia XL or Repinex XL are the preferred cost-effective MR brands (Applicable in primary care).


Rotigotine (Neupro®)
View adult BNF View SPC online View childrens BNF  Track Changes

Neupro Patch 1mg/24hours
Neupro Patch 2mg/24hours
Neupro Patch 3mg/24hours
Neupro Patch 4mg/24hours
Neupro Patch 6mg/24hours
Neupro Patch 8mg/24hours

Restriction: Patients that are NBM or have swallowing difficulties.

Prescribing should be reviewed on discharge from secondary care

04.09.01  Expand sub section  Levodopa
04.09.01  Expand sub section  Monoamine-oxidase-B inhibitors
04.09.01  Expand sub section  Catachol-O-methyltransferase inhibitors to top
04.09.01  Expand sub section  Amantadine
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to children's BNF
click to search
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England
High Cost Drug Approval System

Traffic Light Status Information

Status Description


Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   


Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  


Medicines which can be prescribed in either Primary or Secondary Care.  


These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.